Skip to main content
. 2019 Dec 19;3(24):4177–4186. doi: 10.1182/bloodadvances.2019000939

Table 3.

Treatments and outcomes of 97 iTTP patient episodes

Parameters Values
Number (%) who received TPE 97 (100)
Number (%) who received rituximab before recurrence 38 (39.2)
Days to platelet normalization, median (IQR) 5 (4-7)
Number of TPE to achieve clinical response, median (IQR) 4 (3-5.5)
Outcome, n (%)
 Remission 42 (43.3)
 Recurrence 55 (56.7)
 Exacerbation 39 (40.2)
 Relapse 22 (22.7)
 Relapse after exacerbation 6 (6.2)